Yan Zhang1, Rongxi Yang2, Barbara Burwinkel2, Lutz P Breitling1, Bernd Holleczek1, Ben Schöttker1, Hermann Brenner3. 1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany, Division of Molecular Epidemiology, German Cancer Research Center, Heidelberg, Germany, Molecular Biology of Breast Cancer, Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany and Saarland Cancer Registry, Saarbrücken, Germany. 2. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany, Division of Molecular Epidemiology, German Cancer Research Center, Heidelberg, Germany, Molecular Biology of Breast Cancer, Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany and Saarland Cancer Registry, Saarbrücken, GermanyDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany, Division of Molecular Epidemiology, German Cancer Research Center, Heidelberg, Germany, Molecular Biology of Breast Cancer, Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany and Saarland Cancer Registry, Saarbrücken, Germany. 3. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany, Division of Molecular Epidemiology, German Cancer Research Center, Heidelberg, Germany, Molecular Biology of Breast Cancer, Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany and Saarland Cancer Registry, Saarbrücken, Germany h.brenner@dkfz.de.
Abstract
BACKGROUND: Smoking is a major cause of morbidity and mortality. Smoking-related epigenetic biomarkers may open new avenues to better quantify the adverse health effects of smoking, and to better understanding of the underlying mechanisms. We aimed to evaluate the clinical implications of F2RL3 methylation, a novel epigenetic biomarker of smoking exposure disclosed by recent genome-wide methylation studies. METHODS: Blood DNA methylation at F2RL3 (also known as PAR-4) was quantified in baseline samples of 3588 participants aged 50-75 years in a large population-based prospective cohort study by MALDI-TOF mass spectrometry. Deaths were recorded during a median follow-up of 10.1 years. The associations of methylation intensity and of smoking with all-cause, cardiovascular, cancer and other mortality were assessed by Cox's proportional hazards regression, controlling for potential confounding factors. RESULTS: Lower methylation intensity at F2RL3 was strongly associated with mortality. After adjustment for multiple covariates including smoking, hazard ratios [95% confidence interval (CI)] for death from any cause, cardiovascular disease, cancer or other causes were 2.60 (95% CI, 1.81-3.74), 2.45 (95% CI, 1.28-4.68), 2.94 (95% CI, 1.68-5.14) and 2.39 (95% CI, 1.11-5.16), respectively, in subjects in the lowest quartile of methylation intensity compared with subjects in the highest quartile. The associations with mortality outcomes were much stronger among men than among women. In addition, strong positive associations of smoking with each of the outcomes were substantially weakened, and almost disappeared when controlling for F2RL3 methylation intensity. CONCLUSIONS: F2RL3 methylation is a strong predictor of mortality, including all-cause, cardiovascular, cancer and other mortality. Systemic adverse effects of smoking may be mediated by pathways associated with F2RL3 methylation.
BACKGROUND: Smoking is a major cause of morbidity and mortality. Smoking-related epigenetic biomarkers may open new avenues to better quantify the adverse health effects of smoking, and to better understanding of the underlying mechanisms. We aimed to evaluate the clinical implications of F2RL3 methylation, a novel epigenetic biomarker of smoking exposure disclosed by recent genome-wide methylation studies. METHODS: Blood DNA methylation at F2RL3 (also known as PAR-4) was quantified in baseline samples of 3588 participants aged 50-75 years in a large population-based prospective cohort study by MALDI-TOF mass spectrometry. Deaths were recorded during a median follow-up of 10.1 years. The associations of methylation intensity and of smoking with all-cause, cardiovascular, cancer and other mortality were assessed by Cox's proportional hazards regression, controlling for potential confounding factors. RESULTS: Lower methylation intensity at F2RL3 was strongly associated with mortality. After adjustment for multiple covariates including smoking, hazard ratios [95% confidence interval (CI)] for death from any cause, cardiovascular disease, cancer or other causes were 2.60 (95% CI, 1.81-3.74), 2.45 (95% CI, 1.28-4.68), 2.94 (95% CI, 1.68-5.14) and 2.39 (95% CI, 1.11-5.16), respectively, in subjects in the lowest quartile of methylation intensity compared with subjects in the highest quartile. The associations with mortality outcomes were much stronger among men than among women. In addition, strong positive associations of smoking with each of the outcomes were substantially weakened, and almost disappeared when controlling for F2RL3 methylation intensity. CONCLUSIONS:F2RL3 methylation is a strong predictor of mortality, including all-cause, cardiovascular, cancer and other mortality. Systemic adverse effects of smoking may be mediated by pathways associated with F2RL3 methylation.
Authors: Lutz P Breitling; Rongxi Yang; Bernhard Korn; Barbara Burwinkel; Hermann Brenner Journal: Am J Hum Genet Date: 2011-03-31 Impact factor: 11.025
Authors: Hui-Chen Wu; Lissette Delgado-Cruzata; Julie D Flom; Maya Kappil; Jennifer S Ferris; Yuyan Liao; Regina M Santella; Mary Beth Terry Journal: Epigenetics Date: 2011-01-01 Impact factor: 4.528
Authors: Lutz Philipp Breitling; Katrin Salzmann; Dietrich Rothenbacher; Barbara Burwinkel; Hermann Brenner Journal: Eur Heart J Date: 2012-04-17 Impact factor: 29.983
Authors: Salsabeel H Sabi; Omar F Khabour; Karem H Alzoubi; Caroline O Cobb; Thomas Eissenberg Journal: Inhal Toxicol Date: 2020-04-22 Impact factor: 2.724
Authors: Timothy M Barrow; Hagen Klett; Reka Toth; Jürgen Böhm; Biljana Gigic; Nina Habermann; Dominique Scherer; Petra Schrotz-King; Stephanie Skender; Clare Abbenhardt-Martin; Lin Zielske; Martin Schneider; Alexis Ulrich; Peter Schirmacher; Esther Herpel; Hermann Brenner; Hauke Busch; Melanie Boerries; Cornelia M Ulrich; Karin B Michels Journal: J Pathol Date: 2017-09-29 Impact factor: 7.996
Authors: Matthew T Duvernay; Kayla J Temple; Jae G Maeng; Anna L Blobaum; Shaun R Stauffer; Craig W Lindsley; Heidi E Hamm Journal: Mol Pharmacol Date: 2016-10-26 Impact factor: 4.436
Authors: Steven R H Beach; Man Kit Lei; Mei Ling Ong; Gene H Brody; Meeshanthini V Dogan; Robert A Philibert Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2017-04-24 Impact factor: 3.568
Authors: Allan M Andersen; Philip T Ryan; Fredrick X Gibbons; Ronald L Simons; Jeffrey D Long; Robert A Philibert Journal: J Insur Med Date: 2019-01-31
Authors: Meeshanthini V Dogan; Man-Kit Lei; Steven R H Beach; Gene H Brody; Robert A Philibert Journal: Psychoneuroendocrinology Date: 2016-01-19 Impact factor: 4.905
Authors: Nancy L Saccone; James W Baurley; Andrew W Bergen; Sean P David; Hannah R Elliott; Marilyn G Foreman; Jaakko Kaprio; Thomas M Piasecki; Caroline L Relton; Laurie Zawertailo; Laura J Bierut; Rachel F Tyndale; Li-Shiun Chen Journal: Nicotine Tob Res Date: 2018-03-06 Impact factor: 4.244